AstraZeneca plc (NYSE:AZN) Shares Sold by Gradient Investments LLC

Gradient Investments LLC lessened its position in AstraZeneca plc (NYSE:AZN) by 7.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 33,413 shares of the company’s stock after selling 2,845 shares during the period. Gradient Investments LLC’s holdings in AstraZeneca were worth $1,666,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in AZN. Prime Capital Investment Advisors LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at about $34,000. Allred Capital Management LLC purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $43,000. Simon Quick Advisors LLC increased its holdings in shares of AstraZeneca by 1,515.0% in the 4th quarter. Simon Quick Advisors LLC now owns 969 shares of the company’s stock valued at $48,000 after purchasing an additional 909 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at about $46,000. Finally, Resources Management Corp CT ADV purchased a new position in shares of AstraZeneca in the 3rd quarter valued at about $49,000. Institutional investors own 17.44% of the company’s stock.

Shares of NYSE AZN opened at $50.80 on Thursday. The company has a market cap of $131.66 billion, a PE ratio of 29.36, a price-to-earnings-growth ratio of 1.50 and a beta of 0.46. AstraZeneca plc has a 12 month low of $35.30 and a 12 month high of $51.23. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.92 and a quick ratio of 0.70. The company has a 50-day simple moving average of $49.32 and a 200-day simple moving average of $45.60.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.05. AstraZeneca had a net margin of 8.42% and a return on equity of 38.63%. The business had revenue of $6.13 billion during the quarter, compared to the consensus estimate of $6.07 billion. During the same period in the previous year, the firm posted $0.71 earnings per share. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. On average, analysts anticipate that AstraZeneca plc will post 1.81 EPS for the current year.

A number of brokerages have recently issued reports on AZN. Svb Leerink began coverage on shares of AstraZeneca in a report on Friday, November 22nd. They issued an “outperform” rating for the company. Zacks Investment Research downgraded shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 3rd. ValuEngine downgraded shares of AstraZeneca from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 8th. Cowen restated an “outperform” rating and set a $55.00 target price (up from $48.00) on shares of AstraZeneca in a report on Monday, December 2nd. Finally, Liberum Capital restated a “hold” rating on shares of AstraZeneca in a report on Thursday, October 24th. Five investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. AstraZeneca presently has an average rating of “Hold” and an average target price of $50.35.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Gross Domestic Product (GDP)

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.